High myopia is usually defined as myopia of more than 600 degrees (-6D). It is also known as pathological myopia because it is mostly associated with structural damage to the eye. It is characterized by pathological lengthening of the eye axis, backward expansion of the layers of the eye wall to form a chylomicron, which leads to ischemic pathological changes such as vitreous clouding and liquefaction, retinal and choroidal atrophy, retinal fissures, macular degeneration, etc., resulting in severe impairment of visual function and even blindness. In pathological myopia, genetic factors are the main cause of the disease, and together with a variety of acquired factors cause scleral texture abnormalities, scleral metabolic disorders resulting in scleral thinning, relative inability to withstand intraocular pressure and dilatation, which in turn causes morphological changes in the eye. What is pathological myopia in children and adolescents? International regulations state that myopia is considered pathological high myopia in children and adolescents when myopia progresses beyond -5D under the age of 8, -8D under the age of 12, and -10D under the age of 18. The most effective treatment for pathological myopia is currently: posterior scleral reinforcement. This procedure mechanically strengthens the sclera so that the wall of the eye becomes thicker and firmer and the eye axis does not continue to elongate, slowing myopia progression. It can also improve visual function by improving blood circulation in the choroid and retina, and prevent or reduce the occurrence of serious complications. Numerous studies at home and abroad have shown that posterior scleral consolidation has good efficacy in preventing and treating the progression of pathological myopia, and is currently the main method for treating pathological myopia. Who can undergo posterior scleral consolidation? (1) Myopia with increasing refractive error of more than 1.0D per year; (2) pathological myopia in children; adults with refractive error ≥ 1.8D, eye axis ≥ 27.00mm, and retinal choroidal degeneration in the fundus; (3) scleral chylomalacia in any part of the eye; (4) pathological myopia with a clear genetic predisposition. Exclusion of other ocular diseases.